DNTH's Quality Score fell 1 point on Tue, Nov 10, to 3. Buying slipped from its highest in 20 days (3 chart checks stopped).
Follow DNTH's trial news. Pro members can get an alert when Dianthus Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 689% over three years while the S&P 500 rose 80%.
The other side, how the business stands, the timeline, and its peers, for Pro members.
| Holding it back | 51.7% more shares than a year ago |
| Latest filing | 8-K, Nov 4 |
Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed +5.1% on average, higher 3 of 4 times.
The company says its cash lasts into 2030 (8-K, Nov 4).
Chief Accounting Officer Edward Carr sold 20,000 shares on Sep 17, under a planned sale. 17 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
DNTH is #94 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 94 |
Cash and short-term investments: DNTH $838M, BBIO $1.54B, RCUS $630M, NAMS $628M.
Expected to report Tue Mar 9, after the close (in 119 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“This increase in G&A expenses was primarily due to increased headcount.”
DNTH's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Approximately $1.2 billion of cash as of September 30, 2026 provides expected runway into 2030”
From its results filing (SEC filing · Nov 4)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +0.1% | -3.3% | not yet |
| Aug 4, 2026 | -0.5% | +1.9% | -1.7% |
| May 5, 2026 | +1.7% | +0.2% | -4.5% |
Sales grew in one of the last five years, to $2M in 2025. It lost money in each of the seven years.
RSI 58.9, MACD above signal, below its 50-day, above its 200-day. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: DNTH is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
“We expect to face intense competition from other biopharmaceutical companies that are developing agents for the treatment of autoimmune and inflammatory diseases.”
DNTH scores 3 today, which Breakaway calls Below Average. It is #94 of 281 in Biotech by Quality Score, with 5 of 14 chart checks firing. Up 689% over three years while the S&P 500 rose 80%. Shares: 34.2% more than a year ago (to Dec 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
DNTH scores 3 today, which Breakaway calls Below Average (0 to 5). That is #94 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DNTH's 3.
Expected to report Tue Mar 9, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. DNTH closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.